Enhancing malignant melanoma immunological engagement using sequential therapy with ipilimumab and electrochemotherapy

Trial Profile

Enhancing malignant melanoma immunological engagement using sequential therapy with ipilimumab and electrochemotherapy

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 May 2017

At a glance

  • Drugs Ipilimumab (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Acronyms EMMIE-IP
  • Most Recent Events

    • 07 May 2017 Planned number of patients changed from 30 to 10.
    • 28 Apr 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top